15 February 2018 - - Holzkirchen, Germany-based biosimilar medicines specialist Sandoz, a Novartis division, has launched Glatopa (glatiramer acetate injection) 40 mg/mL following receipt of US FDA approval, the company said.
Glatopa is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone (glatiramer acetate injection) 40 mg/mL three times-a-week therapy for relapsing forms of multiple sclerosis.
Glatopa was developed under a collaboration agreement between Momenta Pharmaceuticals, Inc. and Sandoz and is produced in the US.
Glatopa 40 mg/mL is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Sandoz focuses on generic pharmaceuticals and biosimilars. A division of the Novartis Group, its purpose is to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine.
The company's portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of 10.1 bn.
In 2016, its products reached over 500m patients.